Roivant Sciences Ltd. (ROIV) Wins Orphan Drug Status in Japan for Mosliciguat

In this article, we will be taking a look at the 7 Hot Healthcare Stocks to Buy Right Now. Roivant Sciences Ltd. is one of them.

Roivant Sciences Ltd. (NASDAQ:ROIV) is a clinical-stage biopharmaceutical company focused on accelerating the development of medicines and technologies through its network of subsidiaries, or “Vants.” The company specializes in in-licensing promising drug candidates from larger pharmaceutical firms and advancing them toward commercialization. Its current pipeline includes mosliciguat for pulmonary hypertension associated with interstitial lung disease, brepocitinib for inflammatory diseases, and IMVT-1402, a monoclonal antibody targeting autoimmune conditions.

A key recent milestone for Roivant Sciences Ltd. (NASDAQ:ROIV) is the advancement of mosliciguat, an inhaled soluble guanylate cyclase activator. Licensed from Bayer after its exit from respiratory research, mosliciguat has received orphan drug designation from Japan’s Ministry of Health, Labour and Welfare, granting regulatory benefits and potential market exclusivity. This positions the business’s Pulmovant subsidiary as a key player in addressing an underserved pulmonary hypertension indication with limited treatment options.

In parallel, Roivant Sciences Ltd. (NASDAQ:ROIV)’s brepocitinib program is progressing toward critical Phase 3 data readouts, supporting ongoing investor and analyst optimism. These advancements, along with ROIV’s strategic focus on rare and immune-mediated diseases, make the company one of the hot stocks to buy for investors seeking high-potential biotech opportunities.

While we acknowledge the potential of ROIV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.